Medpace (MEDP) closed at $405.68, up 1.12%, outperforming the S&P 500. Stock rose 2.82% in the past month, trailing the Medical sector. Analysts predict earnings of $2.52 per share with revenue of $529.73 million. Zacks Rank rates Medpace as #1 (Strong Buy), with positive estimate revisions reflecting optimism.

Medpace is traded at a Forward P/E ratio of 35.55, higher than the industry average of 19.51. PEG ratio stands at 1.98, above the industry average of 1.6. Medical Services industry holds a Zacks Industry Rank of 91, in the top 37% of all industries. Stay updated with Zacks.com for stock-shifting metrics.

Zacks Investment Research released a Special Report on Bitcoin’s profit potential. Bitcoin’s returns in past presidential election years were significant. Zacks predicts another surge. Download the report for more insights. Access free stock analysis and recommendations from Zacks Investment Research for the next 30 days.

Source: Zacks Investment Research.

Read more at NASDAQ.: Medpace (MEDP) Outperforms Broader Market: What You Need to Know